Vaccine optimism soars but geopolitics in focus Vaccine optimism soars but geopolitics in focus Vaccine optimism soars but geopolitics in focus

Vaccine optimism soars but geopolitics in focus

Equities 5 minutes to read

Summary:  Optimism returned to the market with US stocks soaring overnight as Powell pledged unwavering support and unlimited ammo for risk assets and Moderna's vaccine proved promising. However the canary in the coalmine, is the deteriorating rhetoric between the US and China and this week will be all about geopolitics and whether the unstable relationship between the US and China is enough to topple the hope trade.


The shine of the overnight moves is fading in Asia trade, with regional bourses falling from session highs, US futures trading in the red, as geopolitical concerns have come to the fore, and vaccine optimism is tempered via the small sample size (45 patients).

 

It is not just tensions between the US and China on the rise, but Australia once again caught between superpowers is bearing the brunt of escalating tensions with China. Diplomatic tensions between the two countries are mounting as Australia has moved to support an investigation and inquiry into the COVID-19 breakout, refusing to be strong-armed by Chinese threats. But the rift goes as far back as Australia's ban on Huawei's participation in 5G rollout on the basis of security ground. 

 

China has moved ahead with the threatened tariffs on Australian barley imports and will impose an anti-dumping duty of 73.6% and an anti-subsidy duty of 6.9% on the commodity as diplomatic tensions between the two nations rise. A move that will no doubt incite ongoing tensions between Australia and China, as Australia, along with 62 other countries, moves in support of an independent investigation into the COVID-19 origins. China is Australia’s largest barley export market and the tariffs will impose significant pressure on Australian growers. But the industry is not a big export earner for Australia as a whole.

 

However, the threats do not stop there and China’s embassy in Canberra has warned of a consumer boycott on Australian goods and produce, causing serious concern to dairy and wine producers fearing they could be the next targets in China’s economic coercion. Watch out Treasury Wine, Bubs Australia and A2 Milk, even companies like Blackmores have relied on CHinese demand for vitamins and supplements.

 

The warning also eluded to a potential bypassing of Australia as a destination for both tourism and education, both tourism and education are major service export industries in Australia - Think Qantas, Sydney Airport, Idp Education. A threat that holds serious repercussions for the Australian economy, as China remains the number one purchaser of both Australian goods and services exports. While de-risking via diversification of Australian exporters into other markets like India and the rest of South East Asia would support long-term goals, reduced Chinese demand for Australian goods and services poses a near term risk for the Australian economy, particularly if other large scale exports like Iron Ore were to be targeted in the worst case scenario. Although at present, China needs Australian iron ore just as much as Australian exporters need China. 

 

These tensions are likely to continue to escalate. Balancing the ideological and national security allegiance with the US and the trade relationship with China leaves Australia in a difficult position. However the AUD struggled to bat an eyelid amidst the strong risk on sentiment, remaining driven by hopes of a sharp recovery in economic activity and tightly correlated with S&P 500 futures. 

 

The US and China have long continued the slow-burn disentanglement and there is no going back to the pre-trade war relationship, but tensions are flaring as the COVID-19 blame game continues.

 

As hostilities mount it appears sentiment toward China is souring in the US, according to Pew research a record 66% of US adults held China in an unfavourable light, a survey high dating as far back as 2005. Another survey from a Washington based consultancy also confirms the shifting sentiment, reporting 40% of respondents said they won’t buy products from China. This potentially marks a new paradigm in the hostilities as the administration in Washington stoke nationalist sentiment across the broad population, fuelling a further breakdown in bilateral relations. 

 

Although the sample size is small, the findings are cause for concern as the upcoming elections in the US may provide increased impetus to elevate geopolitical frictions if they play to US voter support (which will remain a rolling calculus). This would increase the risk of mounting hostilities and fresh tariffs on Chinese imports. On that basis USDCNY bears watching closely as a barometer of China’s intent, with depreciation potentially being a catalyst for renewed risk-off sentiment. 

 

Meanwhile Washington’s rhetoric and actions towards China are becoming increasingly hostile as the COVID-19 pandemic fuels underlying frictions between the two superpowers. 

 

Last week, the Commerce Department decree preventing any chipmaker using American equipment from supplying Huawei without US government approval incited the conflict between the US and China, with Huawei threatening retaliation. The end game of forcing supply chains out of China continues to be dangled with reports surfacing that the US is considering tax breaks for companies to incentive relocating supply chains from China. 

 

In today’s trade, the news that the Nasdaq will be tightening up their IPO rules, a move that will make it harder for Chinese stocks to list, pulled US futures lower. A warning of tightening capital flows between the two nations as well as the lack of accounting transparency that has mired some previous Chinese listings. A letter from President Trump, published on twitter stipulating "the only way forward for the WHO is if it can demonstrate independence from China", also served as reminder that the pandemic is fuelling tensions. 

Disclaimer

The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo or its affiliates.

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK Limited (“Saxo”) is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo holds a Type 1 Regulated Activity (Dealing in Securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged Foreign Exchange Trading); Type 4 Regulated Activity (Advising on Securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products may result in your losses exceeding your initial deposits. Saxo does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo does not take into account an individual’s needs, objectives or financial situation. Please click here to view the relevant risk disclosure statements.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-hk/about-us/awards.

The information or the products and services referred to on this site may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and services offered on this website are not directed at, or intended for distribution to or use by, any person or entity residing in the United States and Japan. Please click here to view our full disclaimer.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc. Android is a trademark of Google Inc.